COMMUNIQUÉS West-GlobeNewswire

Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants
09/07/2026
Daix (France), New York City (New York, United States), July 9, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“ Inventiva ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on the development [...]
Inventiva annonce la finalisation de la restructuration des BSA BEI à la suite de l'émission des Nouveaux BSA BEI
09/07/2026
Daix (France), New York City (New York, États-Unis), le 9 juillet, 2026 – Inventiva (Euronext Paris et NASDAQ : IVA ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement d'une [...]
Canada’s Drug Agency Issues Positive Reimbursement Recommendation for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
09/07/2026
This recommendation represents an important step towards improving access for Canadians living with rare kidney diseases WALTHAM, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: [...]
L’Agence des médicaments du Canada émet une recommandation favorable au remboursement d’EMPAVELI (pegcétacoplan) dans le traitement de la C3G et de la IC-MPGN primaire
09/07/2026
Cette recommandation constitue une avancée majeure vers l’amélioration de l’accès aux soins pour les Canadiens atteints de néphropathies rares WALTHAM, Mass., 09 juill. 2026 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum [...]
Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates
09/07/2026
~ Collaboration will leverage the RaniPill® platform to explore oral delivery of PegBio's proprietary portfolio of novel obesity and metabolic disease molecules ~ ~ Agreement expands Rani's obesity franchise beyond its [...]
Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier
09/07/2026
Denali co-founder and CEO Ryan Watts, Ph.D., to deliver opening plenary address at 2026 AAIC in London on July 12, 2026 Presentation will highlight recent scientific advances and future opportunities to accelerate [...]
Tilray Medical Announces Commercial Launch of Medical Cannabis in Panama, Expanding Patient Access Across Latin America
09/07/2026
Launch of Tilray Medical's first medical cannabis product in Panama strengthens the company's international footprint and supports broader access to regulated cannabinoid-based medicines PANAMA CITY, July 09, 2026 ( [...]
ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results
09/07/2026
PORTLAND, Maine, July 09, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf [...]
GUERBET : Bilan semestriel du contrat de liquidité
09/07/2026
Bilan semestriel du contrat de liquidité Villepinte, le 9 juillet 2026 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, présente aujourd’hui le bilan [...]
SRX Global Board of Directors Authorizes Stock Repurchase Plan of Up to 10 Million Shares or Up to 50% of its Shares Outstanding
09/07/2026
NORTH PALM BEACH, Fla., July 09, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company”, or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments [...]
Ipsen - Juin 2026 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
09/07/2026
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]
Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
09/07/2026
Data Safety Monitoring Committee completed initial review of sentinel dosing observations and recommended continued dosing in Cohort 1 - Dosing of additional patients in Cohort 1 is underway at sites in the US and [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 juin 2026
09/07/2026
DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l’article 222-12-5 du règlement général de l’AMF, les [...]
Ipsen - June 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital
09/07/2026
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
Breckenridge Distillery Launches Breck Vodka Seltzer, a Crisp New Ready-to-Drink Line Born in the Rockies
09/07/2026
The Award-Winning Colorado Craft Distillery Enters the Vodka Seltzer Category with Four Refreshing Flavors at 5% ABV BRECKENRIDGE, Colo., July 09, 2026 (GLOBE NEWSWIRE) -- Breckenridge Distillery , one of the most- [...]
Cynet Releases 2026 Global AI Security Readiness Report
09/07/2026
New report shows more than half of in-house security teams want managed service providers (MSPs) involved when adopting new cybersecurity capabilities, while 60% reporting security incidents BOSTON, July 09, 2026 (GLOBE [...]
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
09/07/2026
First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2 Clinical Development Novel 13-point edited CAR T cell Built with [...]
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
09/07/2026
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus ® (ocrelizumab), including both intravenous and subcutaneous formulations. Agreement advances Teva’s Pivot to [...]
Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome
09/07/2026
Quoin Expects to Initiate Phase 2 Study in 2H 2026, Study Plans to Enroll 6-8 Pediatric and Adult Patients in the U.S. and Europe FDA Expressed No Safety Concerns Over Study Design and Duration of Dosing First-Ever [...]

Pages